0
Abstract: Poster Presentations |

EFFICACY OF CATEGORY III TREATMENT REGIMEN FOR TUBERCULOUS CERVICAL LYMPHADENOPATHY IN INDIAN REVISED NATIONAL TUBERCULOSIS CONTROL PROGRAMME (RNTCP) FREE TO VIEW

Ramakant Dixit, MBBS, MD*; Garvi V. Shelat, MBBS, MD; Samir Gami, MBBS, MD; Sidharth Sharma, MBBS, MD; Savita Jindal, MBBS, MD
Author and Funding Information

Department of Respiratory Medicine and Tuberculosis, JLN Medical College, Ajmer, Ajmer, India


Chest


Chest. 2007;132(4_MeetingAbstracts):641d-642S. doi:10.1378/chest.132.4_MeetingAbstracts.641d
Text Size: A A A
Published online

Abstract

PURPOSE: India has been implementing Revised National Tuberculosis Control Programme (RNTCP), WHO-recommended Directly Observed Treatment Short Course (DOTS) to control tuberculosis (TB). The present study was undertaken to analyze outcome of Category III treatment in RNTCP received by patients having tuberculous cervical lymphadenopathy.

METHODS: 65, FNAC proven cases having tuberculous cervical lymphadenopathy received Category III regimen under RNTCP i.e. 2(HRZ) 3 / 4(HR) 3. The clinical response was noted at the end of treatment. Patients having no response or persistent lymphadenopathy underwent lymph node aspirate or lymph node tissue homogenate for Mycobacterial culture and sensitivity before receiving a re treatment regimen i.e. 2(SHERZ) 3 / 1(HER) 3 / 5(HR) 3, (Category II).

RESULTS: 41 out of 65 patients (63%) responded to Category III treatment, however, 24 patients (36.9%) did not showed response at the end of treatment. 16 patients (24.6%) showing no response with initial regimen, responded to re treatment regimen (Category II), while 5 patients (7.6%) turned out to be having drug resistant disease and responded with reserved drugs. Three patient required surgical resection of glands after completing the re treatment regimen.

CONCLUSION: Six months, thrice weekly, Category III regimen with three drugs in initial intensive phase seems insufficient treatment for patients having tuberculous cervical lymphadenopathy (only 63% response rate with about one fourth patients requiring re treatment regimen).

CLINICAL IMPLICATIONS: There is need for conducting large operational research, considering the number of drugs and duration of therapy in patients receiving Category III treatment for tuberculous cervical lymphadenopathy under RNTCP, especially in areas with primary drug resistance > 4%. Review and timely revision should be the essential component of any Tuberculosis Control Programme.

DISCLOSURE: Dr. Ramakant Dixit, None.

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543